Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$586K Buy
3,095
+155
+5% +$23K ﹤0.01% 1030
2026
Q1
$274K Buy
2,940
+396
+16% +$35.1K ﹤0.01% 1323
2025
Q4
$204K Sell
2,544
-64
-2% -$5.36K ﹤0.01% 1382
2025
Q3
$255K Buy
+2,608
New +$210K ﹤0.01% 1246
2024
Q4
Sell
-2,138
Closed -$224K 1444
2024
Q3
$224K Buy
2,138
+77
+4% +$9.01K ﹤0.01% 1197
2024
Q2
$293K Buy
2,061
+92
+5% +$10.6K ﹤0.01% 1067
2024
Q1
$220K Sell
1,969
-11
-0.6% -$1.31K ﹤0.01% 1158
2023
Q4
$257K Buy
1,980
+64
+3% +$8.82K ﹤0.01% 1096
2023
Q3
$312K Hold
1,916
﹤0.01% 1027
2023
Q2
$351K Buy
1,916
+27
+1% +$3.89K ﹤0.01% 1006
2023
Q1
$252K Buy
+1,889
New +$222K ﹤0.01% 1084

Other funds holding ACLS

Xponance's ACLS Position: Q2 2026 in Review

Xponance increased its Axcelis (ACLS) stake by 5.3% in Q2 2026, buying an estimated $23K and bringing the position to 3,095 shares worth $586K. The position accounts for ﹤0.01% of the portfolio, ranked #1030.

Xponance first reported a position in ACLS in Q1 2023 and has held it in 11 quarters since. 441 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • Xponance held 3,095 shares of Axcelis worth $586K as of Q2 2026.
  • Xponance bought 155 Axcelis shares in Q2 2026, an estimated $23K.
  • Axcelis made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1030 holding.
  • Xponance first reported a position in Axcelis in Q1 2023 and has held it in 11 quarters since.
  • 441 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.